Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Leuk Lymphoma ; 55(11): 2457-65, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24506469

ABSTRACT

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoid neoplasms characterized by aggressive clinical behavior and dismal prognosis. Hepatosplenic γδ T-cell lymphoma (γδ-HSTL) is a particular form of PTCL that arises from a small subset of γ/δ T-cell receptor-expressing lymphocytes. γδ-HSTL has a rapidly progressive course and poor outcome due also to its refractoriness to conventional chemotherapy regimens. The very low incidence of γδ-HSTL, along with its propensity to mimic different pathological entities, makes this lymphoma a true diagnostic challenge. In this review, we highlight the biological and clinical features of γδ-HSTL that contribute to making this lymphoma a mostly incurable disease. Moreover, we provide a new insight into the crosstalk between HSTL clones and the bone marrow, liver and spleen vascular microenvironment, in which neoplastic cells reside and proliferate. We further discuss γδ-HSTL associated molecules that might be proposed as potential targets for novel therapeutic approaches.


Subject(s)
Liver Neoplasms/pathology , Lymphoma, T-Cell, Peripheral/pathology , Receptors, Antigen, T-Cell, gamma-delta/metabolism , Splenic Neoplasms/pathology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Combined Modality Therapy , Humans , Liver Neoplasms/metabolism , Liver Neoplasms/therapy , Lymphoma, T-Cell, Peripheral/metabolism , Lymphoma, T-Cell, Peripheral/therapy , Splenic Neoplasms/metabolism , Splenic Neoplasms/therapy , Stem Cell Transplantation/methods , Treatment Outcome
2.
Blood ; 123(12): 1836-49, 2014 Mar 20.
Article in English | MEDLINE | ID: mdl-24452203

ABSTRACT

Splenic marginal zone lymphoma (SMZL) is a mature B-cell neoplasm characterized by rather indolent clinical course. However, nearly one third of patients experience a rapidly progressive disease with a dismal outcome. Despite the characterization of clone genetics and the recognition of deregulated immunologic stimulation in the pathogenesis of SMZL, little is known about microenvironment dynamics and their potential biological influence on disease outcome. Here we investigate the effect of stroma-intrinsic features on SMZL disease progression by focusing on the microenvironment of the bone marrow (BM), which represents an elective disease localization endorsing diagnostic and prognostic relevance. We show that the quality of the BM stromal meshwork of SMZL infiltrates correlates with time to progression. In particular, we describe the unfavorable prognostic influence of dense CD40 expression by BM stromal cells, which involves the contribution of CD40 ligand (CD40L)-expressing bystander mast cells infiltrating SMZL BM aggregates. The CD40/CD40L-assisted crosstalk between mesenchymal stromal cells and mast cells populating the SMZL microenvironment finds correlation in p53(-/-) mice developing SMZL and contributes to the engendering of detrimental proinflammatory conditions. Our study highlights a dynamic interaction, playing between nonneoplastic elements within the SMZL niche, toward disease progression.


Subject(s)
CD40 Antigens/metabolism , Lymphoma, B-Cell, Marginal Zone/immunology , Lymphoma, B-Cell, Marginal Zone/pathology , Mast Cells/immunology , Mast Cells/pathology , Mesenchymal Stem Cells/immunology , Mesenchymal Stem Cells/pathology , Adult , Aged , Aged, 80 and over , Animals , B-Lymphocytes/immunology , B-Lymphocytes/pathology , CD40 Ligand/metabolism , Cell Differentiation , Cell Proliferation , Cytokines/biosynthesis , Disease Progression , Disease-Free Survival , Female , Genes, p53 , Humans , Inflammation Mediators/metabolism , Lymphoma, B-Cell, Marginal Zone/etiology , Male , Mice , Mice, Inbred BALB C , Mice, Knockout , Middle Aged , Prognosis , Tumor Microenvironment/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...